Hookipa Pharma Inc (NASDAQ:HOOK – Get Rating) – Equities researchers at HC Wainwright issued their FY2027 earnings estimates for Hookipa Pharma in a research note issued to investors on Thursday, March 16th. HC Wainwright analyst A. He expects that the company will post earnings of $0.35 per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Hookipa Pharma’s current full-year earnings is ($0.93) per share.
Separately, Bank of America downgraded shares of Hookipa Pharma from a “buy” rating to an “underperform” rating in a research note on Friday, December 2nd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $7.25.
Hookipa Pharma Trading Down 1.2 %
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Jefferies Financial Group Inc. acquired a new position in shares of Hookipa Pharma in the fourth quarter valued at approximately $849,000. Millennium Management LLC acquired a new position in shares of Hookipa Pharma in the second quarter valued at approximately $1,145,000. Alyeska Investment Group L.P. acquired a new position in shares of Hookipa Pharma in the first quarter valued at approximately $1,434,000. Vanguard Group Inc. increased its stake in shares of Hookipa Pharma by 22.6% in the first quarter. Vanguard Group Inc. now owns 1,118,871 shares of the company’s stock valued at $2,551,000 after buying an additional 206,309 shares during the period. Finally, Two Sigma Investments LP increased its stake in shares of Hookipa Pharma by 311.4% in the fourth quarter. Two Sigma Investments LP now owns 155,806 shares of the company’s stock valued at $126,000 after buying an additional 117,932 shares during the period. Institutional investors own 52.30% of the company’s stock.
About Hookipa Pharma
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
- Get a free copy of the StockNews.com research report on Hookipa Pharma (HOOK)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.